286 related articles for article (PubMed ID: 15195702)
41. Hematopathologic findings in the myeloproliferative disorders.
Dickstein JI; Vardiman JW
Semin Oncol; 1995 Aug; 22(4):355-73. PubMed ID: 7638633
[TBL] [Abstract][Full Text] [Related]
42. [Histomorphologic findings of the bone marrow in chronic myeloproliferative diseases].
Thiele J; Fischer R
Z Hautkr; 1989 Oct; 64(10):903-4, 909-12. PubMed ID: 2686247
[TBL] [Abstract][Full Text] [Related]
43. [Emperipolesis in megakaryocytes in patients with thrombocytosis in the course of myeloproliferative disorders].
Bobik R; Podolak-Dawidziak M; Kiełbiński M; Jeleń M; Wróbel T
Acta Haematol Pol; 1995; 26(2):179-83. PubMed ID: 7653223
[TBL] [Abstract][Full Text] [Related]
44. Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification.
Kvasnicka HM; Thiele J
Pathobiology; 2007; 74(2):63-71. PubMed ID: 17587877
[TBL] [Abstract][Full Text] [Related]
45. Chronic myeloproliferative disorders.
Spivak JL; Barosi G; Tognoni G; Barbui T; Finazzi G; Marchioli R; Marchetti M
Hematology Am Soc Hematol Educ Program; 2003; ():200-24. PubMed ID: 14633783
[TBL] [Abstract][Full Text] [Related]
46. VEGF expression correlates with microvessel density in Philadelphia chromosome-negative chronic myeloproliferative disorders.
Gianelli U; Vener C; Raviele PR; Savi F; Somalvico F; Calori R; Iurlo A; Radaelli F; Fermo E; Bucciarelli P; Bori S; Coggi G; Deliliers GL
Am J Clin Pathol; 2007 Dec; 128(6):966-73. PubMed ID: 18024322
[TBL] [Abstract][Full Text] [Related]
47. AML transformation in 56 patients with Ph- MPD in two well defined populations.
Abdulkarim K; Girodon F; Johansson P; Maynadié M; Kutti J; Carli PM; Bovet E; Andréasson B
Eur J Haematol; 2009 Feb; 82(2):106-11. PubMed ID: 19134023
[TBL] [Abstract][Full Text] [Related]
48. [Megakaryopoiesis in chronic myeloproliferative disorders].
Nagasawa T
Rinsho Ketsueki; 1993 May; 34(5):551-6. PubMed ID: 8315826
[TBL] [Abstract][Full Text] [Related]
49. [The chronic Philadelphia chromosome-negative myeloproliferative syndrome II. Clinical findings, diagnostics and treatment].
Hasselbalch HC; Mourits-Andersen HT; Jensen BA; Jensen MK; Nielsen OJ
Ugeskr Laeger; 2001 Apr; 163(18):2474-7. PubMed ID: 11379260
[TBL] [Abstract][Full Text] [Related]
50. Evidence from molecular genetic and cytogenetic analyses that bone marrow histopathology is reliable in the diagnosis of chronic myeloproliferative disorders.
Werner M; Kaloutsi V; Kausche F; Buhr T; Georgii A
Virchows Arch B Cell Pathol Incl Mol Pathol; 1993; 63(4):199-204. PubMed ID: 8099457
[TBL] [Abstract][Full Text] [Related]
51. Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry.
Spivak JL
Semin Hematol; 2003 Jan; 40(1 Suppl 1):1-5. PubMed ID: 12682874
[TBL] [Abstract][Full Text] [Related]
52. Karyotype findings and molecular analysis of the bcr gene rearrangement supplementing the histologic classification of chronic myeloproliferative disorders.
Werner M; Nolte M; Kaloutsi V; Buhr T; Kausche F; Georgii A
Lab Invest; 1995 Apr; 72(4):405-10. PubMed ID: 7723278
[TBL] [Abstract][Full Text] [Related]
53. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera.
Kvasnicka HM; Thiele J
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):362-71. PubMed ID: 16810612
[TBL] [Abstract][Full Text] [Related]
54. [Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)].
Haferlach T; Bacher U; Kern W; Schnittger S; Haferlach C
Med Klin (Munich); 2007 Sep; 102(9):770-7. PubMed ID: 17879017
[TBL] [Abstract][Full Text] [Related]
55. Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis.
Gianelli U; Iurlo A; Cattaneo D; Bossi A; Cortinovis I; Augello C; Moro A; Savi F; Castelli R; Brambilla C; Bianchi P; Primignani M; Cortelezzi A; Bosari S
Leuk Res; 2015 May; 39(5):525-9. PubMed ID: 25840747
[TBL] [Abstract][Full Text] [Related]
56. Prognostic significance of bone marrow biopsy in essential thrombocythemia.
Annaloro C; Lambertenghi Deliliers G; Oriani A; Pozzoli E; Lambertenghi Deliliers D; Radaelli F; Faccini P
Haematologica; 1999 Jan; 84(1):17-21. PubMed ID: 10091388
[TBL] [Abstract][Full Text] [Related]
57. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
Tefferi A; Thiele J; Vardiman JW
Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
[TBL] [Abstract][Full Text] [Related]
58. Mast cell burden and reticulin fibrosis in the myeloproliferative neoplasms: a computer-assisted image analysis study.
Ahmed A; Powers MP; Youker KA; Rice L; Ewton A; Dunphy CH; Chang CC
Pathol Res Pract; 2009; 205(9):634-8. PubMed ID: 19446406
[TBL] [Abstract][Full Text] [Related]
59. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies.
Georgii A; Buhr T; Buesche G; Kreft A; Choritz H
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():15-29. PubMed ID: 8951769
[TBL] [Abstract][Full Text] [Related]
60. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
